Wise,
This is material - they have just told the market that all "clinical" factors are good i.e. no safety concerns re dosage that were hanging around from legacy MS trials.
The "non clinical" aspects may be related to regulatory / combination therapy partners / recruitment criteria ....ambulant, non-ambulant...or both?
Mark said: "Based on the guidance meeting with the FDA..."
So taking into consideration the FDA guidance this week, ANP are making plans for "global clinical development and commercialization".
Accumulate with ears pinned back
- Forums
- ASX - By Stock
- PER
- Ann: US FDA Type C Meeting for ATL1102 in DMD
Ann: US FDA Type C Meeting for ATL1102 in DMD, page-19
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.0¢ | 8.1¢ | 7.7¢ | $93.21K | 1.183M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 145811 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 33389 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 145811 | 0.080 |
1 | 100000 | 0.078 |
1 | 10000 | 0.077 |
1 | 30000 | 0.075 |
3 | 137616 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 33389 | 1 |
0.084 | 343300 | 4 |
0.085 | 263000 | 1 |
0.086 | 300000 | 1 |
0.087 | 400000 | 1 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |